Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab

Background The aim of this study was to determine whether tumor‐associated immune cells may predict response to therapy and disease outcome in head and neck squamous cell carcinoma (HNSCC) patients receiving induction chemotherapy and cetuximab. Methods Paraffin‐embedded pretreatment biopsy samples...

Full description

Saved in:
Bibliographic Details
Published in:Head & neck 2019-05, Vol.41 (5), p.1237-1245
Main Authors: Ladányi, Andrea, Kapuvári, Bence, Papp, Eszter, Tóth, Erika, Lövey, József, Horváth, Katalin, Gődény, Mária, Remenár, Éva
Format: Article
Language:English
Subjects:
Biopsy
CD134 antigen
CD137 antigen
CD16 antigen
CD20 antigen
CD8 antigen
cetuximab
Chemotherapy
Dendritic cells
Foxp3 protein
Head & neck cancer
head and neck cancer
Immunohistochemistry
Immunotherapy
induction chemotherapy
Lymphocytes
Membrane proteins
Monoclonal antibodies
Neck
Paraffin
Peroxidase
predictive markers
Squamous cell carcinoma
Targeted cancer therapy
tumor‐infiltrating immune cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The aim of this study was to determine whether tumor‐associated immune cells may predict response to therapy and disease outcome in head and neck squamous cell carcinoma (HNSCC) patients receiving induction chemotherapy and cetuximab. Methods Paraffin‐embedded pretreatment biopsy samples from 45 patients with stage III‐IV resectable HNSCC were investigated retrospectively by immunohistochemistry for density of different immune cell types based on expression of CD8, FOXP3, CD134, CD137, PD‐1, CD20, NKp46, dendritic cell lysosomal‐associated membrane protein (DC‐LAMP), CD16, CD68, and myeloperoxidase. Results were analyzed for possible correlations with clinicopathologic parameters, response to therapy, and survival. Results Of the immune cell types studied, we found significant association with response to induction chemotherapy only in the case of DC‐LAMP+ mature dendritic cells and PD‐1+ lymphocytes; density of DC‐LAMP+ cells also correlated with progression‐free survival. Conclusion DC‐LAMP+ mature dendritic cells and PD‐1+ cells may be implicated in response to induction chemotherapy and cetuximab in HNSCC patients.
ISSN:1043-3074
1097-0347
DOI:10.1002/hed.25546